CINECA IRIS Institutional Research Information System

SALVATORE, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.832
AS - Asia 776
EU - Europa 623
SA - Sud America 114
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.400
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.788
SG - Singapore 286
CN - Cina 208
IT - Italia 149
DE - Germania 122
HK - Hong Kong 97
BR - Brasile 83
VN - Vietnam 78
SE - Svezia 73
FR - Francia 55
GB - Regno Unito 47
BG - Bulgaria 46
CA - Canada 36
FI - Finlandia 31
RU - Federazione Russa 29
AT - Austria 24
IN - India 20
SN - Senegal 18
BD - Bangladesh 14
CI - Costa d'Avorio 13
TR - Turchia 13
NG - Nigeria 10
NL - Olanda 9
AR - Argentina 8
IQ - Iraq 8
VE - Venezuela 7
EC - Ecuador 6
JP - Giappone 6
MX - Messico 6
SA - Arabia Saudita 6
ID - Indonesia 5
PK - Pakistan 5
UA - Ucraina 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
CO - Colombia 4
EG - Egitto 4
IL - Israele 4
PH - Filippine 4
AL - Albania 3
CZ - Repubblica Ceca 3
IE - Irlanda 3
MY - Malesia 3
PL - Polonia 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
ES - Italia 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
PY - Paraguay 2
UY - Uruguay 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BH - Bahrain 1
BJ - Benin 1
CL - Cile 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
KH - Cambogia 1
KR - Corea 1
LK - Sri Lanka 1
LV - Lettonia 1
MN - Mongolia 1
MQ - Martinica 1
PE - Perù 1
PR - Porto Rico 1
QA - Qatar 1
RO - Romania 1
RS - Serbia 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.400
Salva come PNG Salva come JPEG
Città #
Woodbridge 231
Ashburn 223
Singapore 171
Fairfield 149
Santa Clara 117
San Jose 113
Hong Kong 94
Boardman 83
Chandler 80
Houston 73
Seattle 73
Cambridge 59
Ann Arbor 51
Shanghai 50
Wilmington 48
Sofia 46
Beijing 44
New York 39
Dallas 35
Pisa 27
Princeton 23
Vienna 20
Hanoi 19
Ottawa 19
Dakar 18
Helsinki 18
Lawrence 18
Los Angeles 18
Des Moines 17
Lauterbourg 16
Medford 16
Bremen 14
Düsseldorf 14
London 14
Abidjan 13
Dong Ket 13
Florence 13
Ho Chi Minh City 13
Dearborn 12
Frankfurt am Main 12
Marseille 12
Munich 12
Buffalo 10
Istanbul 10
Lagos 10
Phoenix 10
Rome 10
Orem 9
Redwood City 9
Columbus 8
Milan 8
Nuremberg 8
São Paulo 8
Toronto 8
Nanjing 7
Turin 7
Guangzhou 6
Lancaster 6
Seacroft 6
Serra 6
Changsha 5
Kunming 5
Montreal 5
Positano 5
Redondo Beach 5
San Diego 5
San Francisco 5
Tokyo 5
Baghdad 4
Boulder 4
Brooklyn 4
Chicago 4
Curitiba 4
Lusciano 4
Memphis 4
Polverigi 4
Rio de Janeiro 4
Shenyang 4
Tianjin 4
Boston 3
Brasília 3
Brent 3
Bắc Ninh 3
Da Nang 3
Dhaka 3
Dublin 3
Guayaquil 3
Hebei 3
Jeddah 3
Johannesburg 3
Leawood 3
Mumbai 3
Nürnberg 3
Paris 3
Stockholm 3
Tashkent 3
Turku 3
Vũng Tàu 3
Warsaw 3
Amsterdam 2
Totale 2.442
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 279
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 218
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer 190
TAS-102 for the treatment of metastatic colorectal cancer 184
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 179
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 178
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 166
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 165
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 162
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 159
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 157
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 154
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 141
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 139
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 124
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 110
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 103
null 98
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 97
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 89
null 85
First-line chemotherapy for mCRC-a review and evidence-based algorithm 82
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 70
Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers 60
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials 55
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study 19
PTEN expression and KRAS mutations in the prediction of benefit from cetuximab plus irinotecan in metastatic colorectal cancer 3
Totale 3.466
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.501
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.501
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022214 3 9 2 3 34 36 4 5 19 13 9 77
2022/2023302 24 48 20 34 31 35 2 14 72 2 18 2
2023/2024160 13 11 24 6 20 27 14 13 4 2 7 19
2024/2025672 5 21 39 26 90 75 38 29 55 99 65 130
2025/20261.002 61 78 47 49 137 129 159 53 71 93 83 42
2026/20271 1 0 0 0 0 0 0 0 0 0 0 0
Totale 3.466